Clinical Trial Update: Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dabrafenib, trametinib, and spartalizumab in BRAF V600E/V600K mutation-positive stage IIIB/IIIC/IIID cutaneous melanoma was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MEKINIST (trametinib)
• Spartalizumab (spartalizumab)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Phase 2 | Status: TERMINATED | Results posted: 2024-10-30